Giuliana Grossi

Dr. Juliana Biondo discusses what the future of treatment for hemophilia A looks like based on ongoing trials.

The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 - 49.2, while the Black population consistently had the highest median state ratios, increasing from 26.7 - 55.4.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

While the FDA decision of Roctavian offers patients with hemophilia A more options, the gene therapy eligibility criteria still pose barriers.

Despite concerns, Dr. Margaret Ragni discusses the significance of the Roctavian's effectiveness for reducing hemophilia A bleeds and improving patient quality of life.

The data provide promising results, yielding a smoking abstinence rate of 26.4% in the intervention group at 18 months.

The approval is supported by positive results from the largest and longest phase 3 study for gene therapy in hemophilia, showing a 52% reduction in annualized bleeding rate compared with baseline rates on routine prophylaxis.

Increasing e-cigarette sales and flavor shifts underscore the need for stricter regulations, according to a CDC Foundation, Truth Initiative.

A new study highlights the benefits of using the hypertonic saline test to determine the appropriate dose of inhaled corticosteroids for managing asthma in children.

Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for those who cannot access enzyme replacement therapy.

Significant cases of missed diagnoses of iron-deficiency emphasize the need for improved screening strategies and proactive measures to address these health risks.

Communities already facing social vulnerabilities are more likely to bear the burden of increased smoke exposure.

Janssen reported significant benefit, and a tolerable profile, for the investigative drug that may become the first indicated to treat HDFN.

COVID-19 vaccination in patients with cystic fibrosis generates antibody responses similar to those in the general population, according to a recent study

Reports from the intervention group show decreased alcohol-related problems, mediated by the change in insomnia severity following treatment.

Findings show patients hospitalized for COVID-19 have an increased 1-year risk of venous thromboembolic disease compared with those hospitalized for influenza (HR, 1.77; 95% CI, 1.36-2.31).

The analysis of 2021 data show lung cancer screening rates increased 8.4% since 2019 to 21.2%.

According to investigators, this is among the largest studies describing the risk of bacteremia in young patients with sickle cell disease.

Among other associations, those in educational attainment, employment status, mental health, and pain episode frequency and severity highlight the need for comprehensive care that considers the psychological well-being of individuals with SCD.

Investigators explain understanding these disparities is crucial for developing targeted interventions to improve screening rates and reduce health inequities.

Amgevita and Idacio exhibited higher rates than methotrexate at both week 24 and week 52 suggesting adalimumab biosimilars provided superior treatment persistence among patients with moderate-to-severe psoriasis.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

The investigation of 11 alternative DMARD therapies in combination with methotrexate shows a lack of economic attractiveness compared with the standard of care.

Criner and colleagues concluded that the 5-year results from the EMPROVE trial demonstrated that Spiration Valve System (SVS) treatment was safe and durable, effectively improving lung function in patients with emphysema

"High-risk patients are more likely to experience comorbid conditions and are more likely to use COPD medications and oxygen, reflecting a higher disease burden," Dr. Ann Cameron explains.

Statistically significant reductions in erythema, scaling, thickness, and overall target plaque scores were observed in both treatment regimens.

Diagnosis, evaluation, and treatment recommendations for pregnant individuals with asthma follow similar principles as for nonpregnant patients, but investigators address specific challenges.

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

These positive outcomes are promising for individuals struggling with narcolepsy, as they provide hope for improved management of their condition. However, Harsh says oxybate therapy is not for everyone.